全球数字聚合酶链式反应 (PCR) 市场 – 行业趋势和 2031 年预测

数字聚合酶链式反应 (PCR) 市场分析和规模

糖尿病患者数量的增加推动了对精确诊断工具的需求，从而推动了数字聚合酶链反应 (PCR) 市场的进步。数字 PCR 技术可以高度灵敏和准确地检测与糖尿病相关的遗传标记，有助于早期诊断和个性化治疗方法。它能够检测罕见突变并以高精度量化目标 DNA，这对于监测糖尿病患者的病情进展和评估治疗效果非常有用。此外，数字 PCR 的自动化功能简化了检测流程，提高了临床实验室的效率，并缩短了患者检测结果的周转时间。

2023 年全球数字聚合酶链反应 (PCR) 市场规模价值 68.3 亿美元，预计到 2031 年将达到 158.6 亿美元，2024 年至 2031 年预测期内的复合年增长率为 11.1%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分       

Market Definition

Digital PCR quantifies and amplifies nucleic acids such as DNA, cDNA, or RNA by partitioning samples into numerous small reactions and detecting positive ones. It offers superior sensitivity and accuracy compared to traditional PCR methods, making it ideal for applications demanding precise detection of minimal nucleic acid inputs or nuanced target amount distinctions. Its efficacy shines in rare sequence detection, copy number variation (CNV) analysis, and gene expression profiling of low-abundance targets.

Digital Polymerase Chain Reaction (PCR) Market Dynamics

Drivers

• Rise in Availability of Digital PCR Diagnostics Leads to Increased Infectious Disease Monitoring

Digital PCR offers unparalleled sensitivity, precision, and accuracy in detecting and quantifying nucleic acids, making it indispensable in various diagnostic applications. Its ability to detect rare mutations, quantify viral load, and assess gene expression levels with high sensitivity has made it a preferred choice in clinical diagnostics, infectious disease monitoring, and oncology. Additionally, advancements such as customized assay design services and integrated systems have further expanded its utility, driving market adoption. As healthcare systems increasingly prioritize precision medicine and personalized diagnostics, the demand for digital PCR technologies is expected to continue rising, fostering market expansion and innovation.

• Growing Research and Development Activities Enhances Speed of Digital PCR Systems

Innovations in product development, driven by R&D efforts, continuously enhance the efficiency, accuracy, and speed of digital PCR systems. These advancements cater to the increasing demand for precise nucleic acid quantification in various fields such as biotechnology, healthcare, and diagnostics. R&D initiatives focus on improving key aspects such as multiplexing capabilities, assay sensitivity, and automation, enabling researchers to address complex biological questions with greater precision and throughput. Consequently, the market witnesses sustained expansion as organizations invest in R&D to stay competitive and meet evolving customer needs for advanced molecular analysis technologies.

Opportunities

• High Prevalence of Cancer Leads to the Adoption of Digital PCR Technology

Digital PCR offers unparalleled sensitivity and precision in detecting and quantifying nucleic acids, making it particularly valuable for cancer diagnosis, monitoring, and treatment. Its ability to detect rare mutations or trace amounts of tumor DNA in bodily fluids enables early detection and personalized therapy approaches. Moreover, as cancer incidence rates continue to rise globally, there is a growing demand for robust molecular diagnostic tools such as digital PCR to support oncology research and clinical practice. This trend has fueled investments in digital PCR technology, driving market growth and innovation in cancer diagnostics and therapeutics.

In 2021, as highlighted by the American Cancer Society's statistics, accentuates the critical role of advanced molecular diagnostics such as Digital PCR in cancer management. With nearly 1.9 million new cases of cancer in the U.S. alone in 2021, there is an urgent need for sensitive and precise diagnostic tools to enable early detection and personalized treatment strategies. Digital PCR's unparalleled sensitivity to detect rare mutations and trace tumor DNA in bodily fluids positions it as a pivotal technology in oncology research and clinical practice, aiding in improving patient outcomes and reducing the global cancer burden.

• Rising Demand for Precision Medicine in the Management of Chronic Disorders

Digital PCR offers unparalleled accuracy and sensitivity in quantifying nucleic acids, making it an ideal tool for the precise diagnosis, monitoring, and personalized treatment of chronic conditions. Its ability to detect rare genetic mutations and variations with high precision allows for tailored therapeutic approaches, enhancing patient outcomes and reducing healthcare costs associated with trial-and-error treatments. Furthermore, the expanding applications of digital PCR in companion diagnostics and pharmacogenomics further bolster its potential in driving advancements in precision medicine.

Amerigo Scientific's expansion of its cell culture portfolio in August 2021 highlights the growing market opportunity in 3D cell culture. It introduces a new 3D cell culture system tailored for scientific applications such as drug discovery, medicine, nanomaterial evaluation, and basic life science research, Amerigo Scientific is capitalizing on the increasing demand for advanced cell culture technologies. This move underscores the industry's momentum towards leveraging innovative solutions to enhance research efficacy and address complex biological challenges.

Restraints/Challenges

• High Cost of Implementation Limits the Adoption of 3D Cell Culture Techniques

As devices become increasingly sophisticated and diverse in their functionalities, conventional PCR systems may struggle to accommodate their unique requirements effectively. This limitation can hinder the ability of PCR technologies to accurately detect and quantify nucleic acids in complex devices, potentially leading to suboptimal results and reduced utility in certain applications.

• Shortage of Skilled Professionals Leads to Potential Errors

Without adequate expertise, users may encounter difficulties in operating complex PCR systems, leading to potential errors in experimental setup, data interpretation, and result analysis. These errors can compromise the accuracy and reliability of nucleic acid quantification, undermining the trust in digital PCR technology. Additionally, the shortage hampers the adoption of advanced PCR techniques, limiting the market growth as organizations struggle to fully leverage the capabilities of digital PCR platforms for research, diagnostics, and therapeutics.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In July 2023, QIAGEN collaborates with Niba Labs to enhance its digital PCR offerings for the biopharma sector, providing tailored dPCR assay design services. This collaboration leverages Niba Labs' expertise in assay development and sample testing, enabling QIAcuity customers to access custom simplex or multiplex assays for nucleic acid quantification
• 2021 年 9 月，赛默飞世尔科技推出了一款全集成数字 PCR 系统，承诺在短短 90 分钟内提供精确一致的结果。该系统代表了 PCR 技术的重大进步，满足了研究人员对快速准确的核酸分析的需求
• 2021 年 7 月，Stilla Technologies 启动了其 sic Color Crystal 数字 PCR 访问计划，让业界可以提前使用配备六个荧光通道的数字 PCR 系统。该计划旨在通过提供能够进行高分辨率核酸分析的先进 PCR 技术来加速研发工作

数字聚合酶链式反应 (PCR) 市场范围

市场根据产品类型、技术、应用、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。  

产品类型

• 数字 PCR 仪器
• 耗材和试剂
• 软件和服务

技术

• 液滴式数字 PCR
• 光束数字PCR

应用

• 临床
• 生命科学与研究
• 其他的

最终用户

• 制药和生物技术公司
• 医院和诊所
• 诊断实验室
• 学术及研究机构
• 参考实验室
• 其他的

分销渠道

• 直接招标
• 零售销售
• 其他的

数字聚合酶链式反应 (PCR) 市场区域分析/见解

根据产品类型、应用、技术、最终用户和分销渠道，市场分为五个显著的部分。   

本市场报告涵盖的国家包括美国、加拿大、墨西哥、德国、法国、意大利、西班牙、英国、瑞士、荷兰、俄罗斯、土耳其、瑞典、比利时、波兰、挪威、芬兰、丹麦、欧洲其他地区、日本、中国、印度、韩国、澳大利亚、新西兰、新加坡、泰国、印度尼西亚、马来西亚、菲律宾、越南、台湾、亚太其他地区、巴西、阿根廷、南美洲其他地区、南非、阿联酋、埃及、巴林、卡塔尔、阿曼、沙特阿拉伯、科威特以及中东和非洲其他地区。   

在北美，由于对该技术的投资不断增加，美国有望在数字 PCR 市场占据主导地位。它占据领先地位，主要归功于主要行业参与者的大量存在。这种主导地位凸显了该国强大的基础设施、技术进步和推动数字 PCR 解决方案采用的战略举措。

在欧洲，德国有望占据市场主导地位，原因包括其强大的工业基础、先进的基础设施和战略地理位置。该国强劲的经济和技术专长使其成为满足欧洲新兴市场对各种产品和服务日益增长的需求的关键参与者。此外，德国积极主动地推进扩张计划并强调创新，进一步促进了其在该地区市场格局中的主导地位。

在亚太地区，由于客户对数字 PCR 技术的偏好日益增加，预计中国将占据市场主导地位。人们越来越意识到数字 PCR 的优势，包括其更高的灵敏度和准确性，这些因素正在推动该技术的采用。此外，中国强劲的生物制药行业和对生命科学研究的投资使该国在采用数字 PCR 等先进分子诊断技术方面处于领先地位。这一趋势为希望扩大其在该地区业务的数字 PCR 制造商和服务提供商提供了巨大的市场机会。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

该市场还为您提供每个国家/地区资本设备医疗支出增长、市场上不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。

竞争格局和数字聚合酶链式反应 (PCR) 市场分析

市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位以及产品类型生命线曲线。以上提供的数据点仅与公司对市场的关注有关。

市场上的一些主要参与者包括：

•  F. HoffmannLa Roche Ltd（瑞士）
•  BioRad Laboratories Inc.（美国）
•  默克集团（德国）
•  赛默飞世尔科技公司（美国）
•  QIAGEN（荷兰）
•  Eppendorf SE（德国）
•  Sysmex Inostics Inc. (日本)
•  Stilla（法国）
•  RainSure Scientific（美国）
•  Accumax（印度）
•  标准 BioTools（美国）
•  JN Medsys（新加坡）
•  VSI Electronics Pvt. Ltd (印度)
•  Precigenome LLC（美国）

SKU-56545